Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)

PURPOSE: We investigated whether irinotecan plus capecitabine improved progression-free survival (PFS) compared with capecitabine alone in patients with human epidermal growth factor 2 (HER2) negative and anthracycline and taxane pretreated metastatic breast cancer (MBC). MATERIALS AND METHODS: A to...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Res Treat
Päätekijät: Park, In Hae, Im, Seock-Ah, Jung, Kyung Hae, Sohn, Joo Hyuk, Park, Yeon Hee, Lee, Keun Seok, Sim, Sung Hoon, Park, Kyong-Hwa, Kim, Jee Hyun, Nam, Byung Ho, Kim, Hee-Jun, Kim, Tae-Yong, Lee, Kyung-Hun, Kim, Sung-Bae, Ahn, Jin-Hee, Lee, Suee, Ro, Jungsil
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Korean Cancer Association 2019
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6333992/
https://ncbi.nlm.nih.gov/pubmed/29458237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2017.562
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia